ALACHUA, FL -- (Marketwired) -- 03/20/18 -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that Dr. Randall M. Toig, M.D. of Chicago, IL has joined its Board of Directors.
Dr. Randall M Toig, M.D. is an associate professor at Northwestern University, Northwestern Memorial Hospital. He is also a well-known physician in the Midwest with a thriving private practice of more than 35 years in obstetrics, gynecology and gynecological oncology, Gold Coast Gynecology of Chicago. He also served at Northwestern Memorial Hospital in Chicago during this same time practicing, teaching and serving on active staff. Dr. Toig is consistently listed in the Top Doctors of Chicago and Guide to America's Top Doctors in his fields.
In addition to his medical practice and teaching, Dr. Toig has served as a consultant to investment bankers evaluating pharmaceutical start-up opportunities. He was also a founder and Board member of Cell Pathways, Inc., a biopharmaceutical start-up that went public in 1997.
Dr. Toig has been an active philanthropist playing an instrumental role as an early contributor to the Friends of Prentice, a foundation focused on the future of women's health, as well as to the Make-A-Wish Foundation. He was actively involved in the preservation and restoration of the historic landmark Chicago Theatre.
"We welcome Dr. Toig to the CTD Holdings Board of Directors," said N. Scott Fine, company Chairman and CEO. "His medical and biotechnology start-up experience will strengthen our Board as we continue to build our global footprint."
"I am honored to have been elected to the Board," said Dr. Toig, "I look forward to working with the Board and Officers of CTD to further the meaningful scientific endeavors being pursued by the CTD team, the patient families, the scientists and other professionals."
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in formal clinical trials. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company's website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Source: CTD Holdings, Inc.